First UK proton beam therapy trial for breast cancer launches
04 January 2023Cambridge researchers are jointly leading the first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer.
Cambridge researchers are jointly leading the first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer.
10 University spinouts that are having an impact in the UK and around the world.
Cambridge scientists have discovered that cancer cells ‘hijack’ a process used by healthy cells to spread around the body, completely changing current ways of thinking around cancer metastasis.
The nine Cambridge researchers were all selected for their exceptional contributions to science.
Med-tech start-up 52 North Health has raised £1 million in its first round of funding to help it develop the NeutroCheck, a fully-integrated clinical, AI and medical device-based system for people living with cancer.
DNA analysis of thousands of tumours from NHS patients has found a ‘treasure trove’ of clues about the causes of cancer, with genetic mutations providing a personal history of the damage and repair processes each patient has been through.
Marcel Gehrung, co-founder and CEO of rapidly growing Cambridge biotech company, Cyted, on revolutionising disease diagnostics and the challenges of building a business during a pandemic.
Every patient with cancer has a story to tell of their journey through diagnosis and treatment. We meet a group of women who are at the centre of pioneering research in Cambridge that’s changing the outcome of ovarian cancer – helping to create treatments that are as unique as their stories.
GE Healthcare, the University of Cambridge and Cambridge University Hospitals have agreed to collaborate on developing an application aiming to improve cancer care, with Cambridge providing clinical expertise and data to support GE Healthcare’s development and evaluation of an AI-enhanced application that integrates cancer patient data from multiple sources into a single interface.
PREDICT Breast and Prostate, powerful online risk communication tools developed by Cambridge researchers, have helped thousands of patients across the world reach better clinical outcomes, avoid unnecessary treatments and suffer less distress.